Alnylam Pharmaceuticals | ALNY - Current Assets


Alnylam Pharmaceuticals reported $5.11B in Current Assets for its fiscal quarter ending in September of 2026.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.27B 43.88M Sep/2026
Agios Pharmaceuticals USD 752.1M 34.43M Sep/2026
Alnylam Pharmaceuticals USD 5.11B 492.49M Sep/2026
Amgen USD 34.36B 598M Sep/2026
Arrowhead Research USD 1.29B 382.19M Sep/2026
BioCryst Pharmaceuticals USD 531.15M 46.47M Sep/2026
BioMarin Pharmaceutical USD 3.92B 50.99M Sep/2026
Incyte USD 5.52B 505.2M Sep/2026
Ionis Pharmaceuticals USD 2.36B 129.77M Sep/2026
Moderna USD 7.34B 1.53B Sep/2026
Neurocrine Biosciences USD 2.01B 370.7M Sep/2026
Novartis USD 28.75B 2.14B Sep/2026
PTC Therapeutics USD 2.54B 79.58M Sep/2026
Regeneron Pharmaceuticals USD 20.8B 2.35B Sep/2026
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Sanofi EUR 31.52B 1.36B Jun/2026
Sarepta Therapeutics USD 2.27B 49.06M Sep/2026
Takeda JPY 3T 153.11B Sep/2026
Tectonic Therapeutic USD 231.1M 8.79M Jun/2026
Ultragenyx Pharmaceutical USD 544M 62M Sep/2026
Vertex Pharmaceuticals USD 11.69B 857.4M Sep/2026
Xencor USD 498.66M 24.55M Sep/2026